(Reuters) – Britain’s drug regulator on Thursday approved GSK and Vir Biotechnology’s antibody based COVID-19 treatment, Xevudy, for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease.
The approval comes as GSK separately announced the treatment has shown to work against the Omicron variant.